Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021
Previous Archive
14 May 2019 | Story Thabo Kessah | Photo Tsepo Moeketsi
Prof Ashafa
Prof Ashafa’s research documents plants used by the Basotho in the management of different ailments.

The Phytomedicine and Phytopharmacology Research Programme (PPRP) in the Department of Plant Sciences on the Qwaqwa Campus researches the biological effects of medicinal plants used in the folkloric medicine of the Eastern Free State, particularly to explore the values and contribution of indigenous knowledge systems (IKS) towards broader scientific research. This is according to the programme’s principal investigator and researcher, NRF C2-rated researcher, Professor Anofi Ashafa. 

 “Our research is mainly aimed at documenting plants used by the Basotho in the management of different ailments and to further discover, isolate, and purify active phytoconstituents that are responsible for disease curation or amelioration, thereby assisting in the global promotion of accessible and affordable medication in developing countries,” said Prof Ashafa. 

Since 2012, the PPRP has worked extensively on Basotho medicinal plants (BMP) used as antimicrobials, antioxidants, antidiabetics, antitubercular, anticancer, anthelmintic, and antidiarrheal agents, starting from biological activities up to the  evaluation of the toxicity of these plants for the kidney, liver, and heart functions in order to establish safe dosage parameters. These activities have led to the discovery of four potent antidiabetic biomolecules that are awaiting the processes of patency and commercialisation. Additional outputs include 104 published peer-reviewed articles , 7 postdoctoral fellows, 6 PhDs, 9 master’s, and 16 honours graduates. 

“Our research informs teaching and the development of expertise in ethnobotany, 
phytomedicine, and phytopharmacology in order to contribute to the National Development Plan (NDP) through human capacity development, skills, and knowledge transfer.

The group is also investigating some medicinal plants on the endangered red list of the South African National Biodiversity Institute (SANBI), through micropropagation and field trials as well as proposing conservation strategies to preserve these valuable species.

The PPRP consists of postdoctoral fellows, PhD, master’s, and honours students and research is done in collaboration with several local and international universities as well as the Agricultural Research Council of South Africa. 


News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept